NCT02448485 High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis (Tyrolean Aortic Stenosis Study-2)
| NCT ID | NCT02448485 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University Innsbruck |
| Condition | Aortic Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2015-06 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2015-06 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TASS-2 (Tyrolean Aortic Stenosis Study-2) aims to characterize the clinical value of minimally elevated troponin T plasma levels both in patients with asymptomatic and symtomatic aortic stenosis.
Eligibility Criteria
Inclusion Criteria: * aortic stenosis detected by echocardiography / invasively Exclusion Criteria: * acute coronary syndrome * endocarditis
Contact & Investigator
Wolfgang Dichtl, MD, PhD
PRINCIPAL INVESTIGATOR
Medical University Innsbruck
Frequently Asked Questions
Who can join the NCT02448485 clinical trial?
This trial is open to participants of all sexes, studying Aortic Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02448485 currently recruiting?
Yes, NCT02448485 is actively recruiting participants. Contact the research team at dichtl@me.com for enrollment information.
Where is the NCT02448485 trial being conducted?
This trial is being conducted at Innsbruck, Austria.
Who is sponsoring the NCT02448485 clinical trial?
NCT02448485 is sponsored by Medical University Innsbruck. The principal investigator is Wolfgang Dichtl, MD, PhD at Medical University Innsbruck. The trial plans to enroll 10,000 participants.